

# Stergios Kechagias

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1251763/publications.pdf>

Version: 2024-02-01

91  
papers

10,450  
citations

117625

34  
h-index

43889

91  
g-index

93  
all docs

93  
docs citations

93  
times ranked

10660  
citing authors

#	ARTICLE	IF	CITATIONS
1	Disease Progression Modeling for Economic Evaluation in Nonalcoholic Fatty Liver Disease—A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 283-298.	4.4	7
2	Impact on follow-up strategies in patients with primary sclerosing cholangitis. <i>Liver International</i> , 2023, 43, 127-138.	3.9	15
3	Risk for hepatic and extrahepatic outcomes in nonalcoholic fatty liver disease. <i>Journal of Internal Medicine</i> , 2022, 292, 177-189.	6.0	11
4	Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 60-69.	1.5	3
5	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	4.9	20
6	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. <i>Journal of Hepatology</i> , 2022, 76, 1013-1020.	3.7	66
7	Repeated measurements of noninvasive fibrosis tests to monitor the progression of nonalcoholic fatty liver disease: A long-term follow-up study. <i>Liver International</i> , 2022, 42, 1545-1556.	3.9	6
8	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2008-e2020.	3.6	27
9	Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. <i>Hormones</i> , 2022, 21, 349-368.	1.9	12
10	Autoantibodies Associated with Autoimmune Liver Diseases in a Healthy Population: Evaluation of a Commercial Immunoblot Test. <i>Diagnostics</i> , 2022, 12, 1572.	2.6	1
11	Hepatic patatin-like phospholipase domain-containing 3 levels are increased in 1148M risk allele carriers and correlate with NAFLD in humans. <i>Hepatology Communications</i> , 2022, 6, 2689-2701.	4.3	5
12	Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2021, 115, 154439.	3.4	41
13	Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 437-442.	1.5	4
14	A Dynamic Aspartate to Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease. <i>Hepatology Communications</i> , 2021, 5, 1021-1035.	4.3	23
15	Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction. <i>JHEP Reports</i> , 2021, 3, 100218.	4.9	26
16	Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. <i>BMC Gastroenterology</i> , 2021, 21, 180.	2.0	5
17	A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy. <i>Journal of Hepatology</i> , 2021, 75, 98-107.	3.7	25
18	Review article: nonalcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1013-1025.	3.7	47

#	ARTICLE	IF	CITATIONS
19	Usefulness of Clinical and Laboratory Criteria for Diagnosing Autoimmune Liver Disease among Patients with Systemic Lupus Erythematosus: An Observational Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3820.	2.4	4
20	Low hepatic manganese concentrations in patients with hepatic steatosis – A cohort study of copper, iron and manganese in liver biopsies. <i>Journal of Trace Elements in Medicine and Biology</i> , 2021, 67, 126772.	3.0	15
21	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	3.7	149
22	Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1592-1599.e8.	4.4	21
23	Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 848-859.	1.5	15
24	Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154183.	3.4	39
25	The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 1069-1078.	3.9	31
26	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020, 73, 505-515.	3.7	279
27	Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes. <i>Clinical and Experimental Immunology</i> , 2020, 203, 22-31.	2.6	11
28	Modifiers of Liver-Related Manifestation in the Course of NAFLD. <i>Current Pharmaceutical Design</i> , 2020, 26, 1062-1078.	1.9	8
29	Model-inferred mechanisms of liver function from magnetic resonance imaging data: Validation and variation across a clinically relevant cohort. <i>PLoS Computational Biology</i> , 2019, 15, e1007157.	3.2	6
30	Alcohol consumption in non-alcoholic fatty liver disease – harmful or beneficial?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 311-313.	1.5	3
31	Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1214-1222.	3.7	55
32	Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1148-1156.e4.	4.4	71
33	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	13.7	818
34	PNPLA3 variant M148 causes resistance to starvation-mediated lipid droplet autophagy in human hepatocytes. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 343-356.	2.6	44
35	Liver R2* is affected by both iron and fat: A dual biopsy-validated study of chronic liver disease. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 325-333.	3.4	22
36	Cardiovascular risk factors in non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 197-204.	3.9	75

#	ARTICLE	IF	CITATIONS
37	Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. <i>Hepatology Communications</i> , 2018, 2, 48-57.	4.3	200
38	Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies. <i>Hepatology Communications</i> , 2018, 2, 199-210.	4.3	102
39	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. <i>Hepatology</i> , 2017, 65, 1557-1565.	7.3	1,294
40	Using a 3% Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis, Based on Results From Histopathology Analysis. <i>Gastroenterology</i> , 2017, 153, 53-55.e7.	1.3	51
41	Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1-7.	1.5	32
42	Collagen proportion area is an independent predictor of longterm outcome in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2017, 66, S52.	3.7	1
43	Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. <i>Journal of Hepatology</i> , 2017, 67, 1265-1273.	3.7	730
44	SAF score and mortality in NAFLD after up to 41 years of follow-up. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 87-91.	1.5	32
45	Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 159-165.	1.5	60
46	Automated quantification of steatosis: agreement with stereological point counting. <i>Diagnostic Pathology</i> , 2017, 12, 80.	2.0	15
47	Natural History of NAFLD/NASH. <i>Current Hepatology Reports</i> , 2017, 16, 391-397.	0.9	102
48	Reply. <i>Hepatology</i> , 2016, 64, 310-311.	7.3	0
49	Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. <i>Liver International</i> , 2016, 36, 1688-1695.	3.9	54
50	Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1126-1132.	1.5	13
51	Effect of oral diclofenac intake on faecal calprotectin. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 28-32.	1.5	28
52	Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. <i>PLoS ONE</i> , 2016, 11, e0167776.	2.5	17
53	Comparing hepatic 2D and 3D magnetic resonance elastography methods in a clinical setting – Initial experiences. <i>European Journal of Radiology Open</i> , 2015, 2, 66-70.	1.6	10
54	Consistent intensity inhomogeneity correction in water-fat MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 468-476.	3.4	23

#	ARTICLE	IF	CITATIONS
55	Visual assessment of biliary excretion of Gd-EOB-DTPA in patients with suspected diffuse liver disease – A biopsy-verified prospective study. <i>European Journal of Radiology Open</i> , 2015, 2, 19-25.	1.6	7
56	Phosphatidylethanol Compared with Other Blood Tests as a Biomarker of Moderate Alcohol Consumption in Healthy Volunteers: A Prospective Randomized Study. <i>Alcohol and Alcoholism</i> , 2015, 50, 399-406.	1.6	90
57	Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease. <i>Translational Research</i> , 2015, 165, 658-666.	5.0	28
58	Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. <i>Hepatology</i> , 2015, 61, 1547-1554.	7.3	1,683
59	Gastroduodenal Changes Two Years After Eradication of <i>Helicobacter pylori</i> in a Population-Based Cohort. <i>Gastroenterology Research</i> , 2015, 8, 171-177.	1.3	0
60	Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. <i>PLoS Medicine</i> , 2014, 11, e1001680.	8.4	507
61	Increased thrombin generation in splanchnic vein thrombosis is related to the presence of liver cirrhosis and not to the thrombotic event. <i>Thrombosis Research</i> , 2014, 134, 455-461.	1.7	16
62	Separation of advanced from mild hepatic fibrosis by quantification of the hepatobiliary uptake of Gd-EOB-DTPA. <i>European Radiology</i> , 2013, 23, 174-181.	4.5	61
63	The international normalized ratio according to Owren in liver disease: Interlaboratory assessment and determination of international sensitivity index. <i>Thrombosis Research</i> , 2013, 132, 346-351.	1.7	10
64	Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 108-115.	1.5	42
65	Effects of moderate red wine consumption on liver fat and blood lipids: a prospective randomized study. <i>Annals of Medicine</i> , 2011, 43, 545-554.	3.8	46
66	Resistin is Associated with Breach of Tolerance and Anti-nuclear Antibodies in Patients with Hepatobiliary Inflammation. <i>Scandinavian Journal of Immunology</i> , 2011, 74, 463-470.	2.7	13
67	Transient Increase in HDL-Cholesterol During Weight Gain by Hyperalimentation in Healthy Subjects. <i>Obesity</i> , 2011, 19, 812-817.	3.0	7
68	Natural history of chronic gastritis in a population-based cohort. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 540-549.	1.5	15
69	The Effects of Capsaicin on Gastrin Secretion in Isolated Human Antral Glands: Before and After Ingestion of Red Chilli. <i>Digestive Diseases and Sciences</i> , 2009, 54, 491-498.	2.3	23
70	Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 366-374.	1.5	183
71	Separation of advanced from mild fibrosis in diffuse liver disease using 31P magnetic resonance spectroscopy. <i>European Journal of Radiology</i> , 2008, 66, 313-320.	2.6	39
72	Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. <i>Gut</i> , 2008, 57, 649-654.	12.1	164

#	ARTICLE	IF	CITATIONS
73	Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study. <i>Journal of Hepatology</i> , 2007, 47, 135-141.	3.7	242
74	Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 821-830.	3.7	58
75	690 Statins in patients with elevated liver enzymes because of non-alcoholic fatty liver disease (NAFLD): A clinical and histopathological follow-up study. <i>Journal of Hepatology</i> , 2006, 44, S254-S255.	3.7	4
76	Long-term follow-up of patients with NAFLD and elevated liver enzymes. <i>Hepatology</i> , 2006, 44, 865-873.	7.3	2,038
77	Letter to the editor. <i>Clinical Transplantation</i> , 2005, 19, 571-571.	1.6	1
78	Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting. <i>Modern Pathology</i> , 2005, 18, 912-916.	5.5	100
79	Expression of vanilloid receptor-1 in epithelial cells of human antral gastric mucosa. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 775-782.	1.5	17
80	Treatment of anaemia in inflammatory bowel disease with iron sucrose. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 454-458.	1.5	56
81	Morphological examination of the termination pattern of substance P-immunoreactive nerve fibers in human antral mucosa. <i>Regulatory Peptides</i> , 2002, 107, 79-86.	1.9	3
82	Morphological Support for Paracrine Inhibition of Gastric Acid Secretion by Nitric Oxide in Humans. <i>Scandinavian Journal of Gastroenterology</i> , 2001, 36, 1016-1021.	1.5	16
83	Influence of Age, Sex, and Helicobacter pylori Infection Before and After Eradication on Gastric Alcohol Dehydrogenase Activity. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 508-512.	2.4	10
84	Influence of age, sex, and Helicobacter pylori infection before and after eradication on gastric alcohol dehydrogenase activity. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 508-12.	2.4	3
85	Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 728-732.	2.4	23
86	Reliability of Breath-Alcohol Analysis in Individuals with Gastroesophageal Reflux Disease. <i>Journal of Forensic Sciences</i> , 1999, 44, 814-818.	1.6	23
87	Reliability of breath-alcohol analysis in individuals with gastroesophageal reflux disease. <i>Journal of Forensic Sciences</i> , 1999, 44, 814-8.	1.6	1
88	Low-dose aspirin decreases blood alcohol concentrations by delaying gastric emptying. <i>European Journal of Clinical Pharmacology</i> , 1997, 53, 241-246.	1.9	33
89	Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol. <i>British Journal of Clinical Pharmacology</i> , 1997, 44, 521-526.	2.4	79
90	Immunocytochemical evidence for vesicular storage of glutamate in cat spinocervical and cervicothalamic tract terminals. <i>Brain Research</i> , 1995, 675, 316-320.	2.2	9

#	ARTICLE	IF	CITATIONS
91	Compartmentation of glutamate and glutamine in the lateral cervical nucleus: Further evidence for glutamate as a spinocervical tract neurotransmitter. <i>Journal of Comparative Neurology</i> , 1994, 340, 531-540.	1.6	17